Trial · NCT04989140
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT04989140, Phase 4, Unknown, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide. Trials, record NCT04989140. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04989140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
- NCT number
- NCT04989140
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
- First posted
- 2021-08-04
- Last updated
- 2021-08-19
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | Time Frame: From date of enrollment until the date of first documented progression, assessed up to 24 months | From enrollment to first disease progression |
| Secondary | Adverse events assessment | Each cycle, up to 24 months of follow-up. | Number of adverse events according to symptoms, physical examination and scheduled laboratory tests |
| Secondary | Overall survival | At baseline, on day 1 of each cycle, and after 2, 3,4,5,7,9,11,13,16,19,22, 25 and 28 months of follow-up | From enrollment to death with follow-up |
| Secondary | Overall response rate | At baseline, on day 1 of each cycle, and after 2, 3,4,5,7,9,11,13,16,19,22, 25 and 28 months of follow-up | Overall response rate included Complete Response (CR), Very good partial response (VGPR) and PR, before the new treatment, two consecutive evaluations are in line with defined criteria in order to confirm the efficacy evaluation. |
| Secondary | Time to next treatment | At baseline, on day 1 of each cycle, and after 2, 3,4,5,7,9,11,13,16,19,22, 25 and 28 months of follow-up | From enrollment to the time next treatment is administrated |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04989140
GET https://conductscience.org/api/trials/v1/NCT04989140/registered